CORT - Corcept Therapeutics Corp Total Debt to Capital

Corcept Therapeutics (CORT) acts as a biopharmaceutical innovator, investing in the development of unique receptor modulators for metabolic correction. The company strives for leadership in the therapy of endocrine pathologies and oncology through cortisol control and patent protection. Automated 24/7 screening platforms are accelerating the drug discovery process. This daily price chart illustrates that the total debt-to-equity ratio is 0.01.

The financial stability of Corcept Therapeutics (CORT) is based on the balance between revenues from Cushing's syndrome therapy and the costs of expansion into oncology. Analyzing this debt-to-equity chart, an investor can see the share of external liabilities within the asset structure, where a rising ratio signals increased credit risk, while a decrease indicates growing autonomy and a higher fair value of the business.